Hutchmed (China) Limited HUTCHMED Selected for Certain Hang Seng Indexes
23 Août 2021 - 8:00AM
RNS Non-Regulatory
TIDMHCM
Hutchmed (China) Limited
23 August 2021
Press Release
HUTCHMED Selected as Constituent of Certain Hang Seng
Indexes
Hong Kong, Shanghai & Florham Park, NJ - Monday, August 23,
2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:
13) today announces that HUTCHMED has been selected as a
constituent stock of several indexes administered by Hang Seng
Indexes Company Limited ("Hang Seng"), including the Hang Seng
Composite Index , in accordance with the latest index series
release by Hang Seng, with effect from Monday, September 6,
2021.
The Hang Seng Composite Index offers a comprehensive Hong Kong
market benchmark that covers about the top 95(th) percentile of the
total market capitalization of companies listed on the Main Board
of The Stock Exchange of Hong Kong Limited. HUTCHMED has also been
selected for six other indexes of Hong Kong-listed stocks,
including the Hang Seng Healthcare Index and the Hang Seng Hong
Kong-Listed Biotech Index.
In addition to the above indexes of stocks listed in Hong Kong,
Hang Seng has also selected HUTCHMED for inclusion in six
cross-market indexes, including the Hang Seng Stock Connect China
500 Index, which aims to measure the overall performance of the 500
largest Chinese companies in terms of market capitalization listed
in Hong Kong and/or mainland China that are eligible for Northbound
or Southbound trading under the Stock Connect schemes.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery, global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. A dedicated organization of over 1,400
personnel has advanced eleven cancer drug candidates from in-house
discovery into clinical studies around the world, with its first
three oncology drugs now approved and marketed. For more
information, please visit: www.hutch-med.com or follow us on
LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect HUTCHMED's current expectations regarding future
events, including its inclusion as a constituent stock of the Hang
Seng Composite Index and its ability to meet the eligibility
criteria for trading via the southbound trading link of Stock
Connect. Forward-looking statements involve risks and
uncertainties. Such risks and uncertainties include, among other
things, assumptions regarding HUTCHMED's financial condition and
results of operations, general economic, regulatory and political
conditions and the impact of COVID-19 on any of the foregoing.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. For further discussion of these and other
risks, see HUTCHMED's filings with the U.S. Securities and Exchange
Commission, on AIM and with The Stock Exchange of Hong Kong
Limited. HUTCHMED undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
HUTCHMED@fticonsulting.com
Asia - Zhou Yi, Brunswick +852 97 83 6894 (Mobile)
HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAXLLFLFVLXBBZ
(END) Dow Jones Newswires
August 23, 2021 02:00 ET (06:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024